4.6 Review

The joint-gut axis in inflammatory bowel diseases

期刊

JOURNAL OF CROHNS & COLITIS
卷 4, 期 3, 页码 257-268

出版社

OXFORD UNIV PRESS
DOI: 10.1016/j.crohns.2009.11.005

关键词

Inflammatory bowel diseases; Ulcerative colitis; Crohn's disease; Extraintestinal manifestations; Spondyloarthropathies; Arthralgia

向作者/读者索取更多资源

Inflammatory bowel diseases, Crohn's disease and ulcerative colitis, are associated with a variety of extraintestinal manifestations. The most common extraintestinal manifestation, articular involvement, occurs in 16% to 33% of inflammatory bowel disease patients. These arthropathies may increase morbidity, resulting in a worse quality of life compared with inflammatory bowel disease patients without arthropathies. Thus, arthropathies in inflammatory bowel diseases represent a major medical problem in these patients. Arthritis associated with inflammatory bowel diseases is one of the diseases captured under the umbrella of spondyloarthritis. Spondyloarthritis is a group of inflammatory diseases with overlapping features and is linked to Human Leukocyte Antigen-B27. Arthropathy in inflammatory bowel diseases is clinically divided into peripheral and axial involvement. Peripheral arthritis often flares with relapses of bowel disease resulting in a different treatment approach than axial arthritis in which the course is independent of inflammatory bowel disease activity. Definitions, prevalence, pathophysiology and treatment of the arthropathies commonly seen in inflammatory bowel diseases such as peripheral arthritis, dactylitis, enthesitis, arthralgia, sacroiliitis, inflammatory back pain and ankylosing spondylitis are summarized. (C) 2009 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Rheumatology

Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis

Casper Webers, Augusta Ortolan, Alexandre Sepriano, Louise Falzon, Xenofon Baraliakos, Robert B. M. Landewe, Sofia Ramiro, Desiree van der Heijde, Elena Nikiphorou

Summary: This study aims to provide updated evidence on the efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) for the revision of management recommendations. The results showed significant efficacy of tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i), while IL-23 inhibitors failed to demonstrate relevant effects. Observational studies are required to confirm the long-term safety of IL-17i.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Review Rheumatology

Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

Augusta Ortolan, Casper Webers, Alexandre Sepriano, Louise Falzon, Xenofon Baraliakos, Robert B. M. Landewe, Sofia Ramiro, Desiree van der Heijde, Elena Nikiphorou

Summary: This study updated the evidence of non-biological treatments for axSpA, providing a basis for the 2022 ASAS-EULAR recommendations. The results showed that education, exercise, and NSAIDs were efficacious in axSpA.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

External validation of the alternative Ankylosing Spondylitis Disease Activity Score in three randomized clinical trials of ixekizumab

Augusta Ortolan, Sofia Ramiro, Roberta Ramonda, Desiree van der Heijde

Summary: The altASDAS index is a valid tool for assessing disease activity in axial SpA patients when patient global assessment is unavailable. It has been shown to be both truthful and discriminative in an external cohort, demonstrating its usefulness in clinical practice.

RHEUMATOLOGY (2023)

Review Rheumatology

Treating spondyloarthritis early: does it matter? Results from a systematic literature review

Dafne Capelusnik, Diego Benavent, Desiree van der Heijde, Robert Landewe, Denis Poddubnyy, Astrid van Tubergen, Louise Falzon, Victoria Navarro-Compan, Sofia Ramiro

Summary: This study conducted a systematic literature review to summarize the relationship between early treatment and treatment clinical response in patients with SpA. It found that early treatment was associated with better outcomes in patients with non-radiographic axSpA and symptom duration of less than 5 years, but no differences in response to treatment were found in radiographic axSpA or in patients with longer symptom duration.

RHEUMATOLOGY (2023)

Article Rheumatology

The effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter?

Casper Webers, Uta Kiltz, Juergen Braun, Desiree van der Heijde, Annelies Boonen

Summary: Treating active SpA improves depressive symptoms, especially with TNF inhibitors (TNFis) which have a stronger effect mainly due to their impact on disease activity.

RHEUMATOLOGY (2023)

Article Rheumatology

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials

Desiree van der Heijde, Atul Deodhar, Xenofon Baraliakos, Matthew A. Brown, Hiroaki Dobashi, Maxime Dougados, Dirk Elewaut, Alicia M. Ellis, Carmen Fleurinck, Karl Gaffney, Lianne S. Gensler, Nigil Haroon, Marina Magrey, Walter P. Maksymowych, Alexander Marten, Ute Massow, Marga Oortgiesen, Denis Poddubnyy, Martin Rudwaleit, Julie Shepherd-Smith, Tetsuya Tomita, Filip van den Bosch, Thomas Vaux, Huji Xu

Summary: The BE MOBILE 1 and BE MOBILE 2 trials demonstrated that bimekizumab, a dual IL-17A and IL-17F inhibitor, improved efficacy outcomes in patients with axial spondyloarthritis (axSpA) and was well tolerated. These findings support the use of bimekizumab as a potential treatment option for axSpA.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Review Rheumatology

Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Andreas Kerschbaumer, Alexandre Sepriano, Sytske Anne Bergstra, Josef S. Smolen, Desiree van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E. Pope, Tsutomu Takeuchi, Kimme L. Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja A. Stamm, Jan W. Schoones, Robert B. M. Landewe

Summary: This study aimed to update the evidence on the efficacy of DMARDs and provide information for the 2022 update of EULAR recommendations for RA management. A systematic literature review was conducted to investigate the efficacy of cs, b, biosimilar, and tsDMARDs in RA patients. The results showed that csDMARDs combined with short-term glucocorticoids in early RA were as effective as bDMARD+MTX combination therapy. JAK inhibitors were effective in different patient populations. Tapering of DMARDs was feasible for some patients who could maintain low disease activity or achieve remission.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Review Rheumatology

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Alexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, Josef S. Smolen, Desiree van der Heijde, Roberto Caporali, Christopher J. Edwards, Patrick Verschueren, Savia de Souza, Janet Pope, Tsutomu Takeuchi, Kimme Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja Stamm, Jan W. Schoones, Robert B. M. Landewe

Summary: This study conducted a systematic literature review (SLR) to evaluate the safety of synthetic and biological disease-modifying antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA). The results indicated that bDMARDs were associated with an increased risk of serious infections compared to csDMARDs, while JAK inhibitors (JAKi) showed higher risk of herpes zoster infections. The risks of malignancies, major adverse cardiovascular events (MACE), and venous thromboembolism (VTE) were similar among different treatments.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Review Rheumatology

Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Sytske Anne Bergstra, Alexandre Sepriano, Andreas Kerschbaumer, Desiree van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E. Pope, Tsutomu Takeuchi, Kimme L. Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja A. Stamm, Jan W. Schoones, Josef S. Smolen, Robert B. M. Landewe

Summary: This systematic literature review examines the efficacy, duration of use, and safety of glucocorticoids (GCs) in the management of rheumatoid arthritis (RA). The study confirms the effectiveness of GCs in treating RA, with most patients able to stop GCs within 12-24 months. However, the use of GCs also carries well-known safety risks, including osteoporotic fractures, serious infections, diabetes, and mortality.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Letter Rheumatology

Response to: Correspondence on ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update by Ramiro et al

Sofia Ramiro, Elena Nikiphorou, Alexandre Sepriano, Augusta Ortolan, Casper Webers, Xenofon Baraliakos, Robert B. M. Landewe, Desiree van der Heijde

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

ASAS consensus definition of early axial spondyloarthritis

Victoria Navarro-Compan, Diego Benavent, Dafne Capelusnik, Desiree van der Heijde, Robert B. M. Landewe, Denis Poddubnyy, Astrid van Tubergen, Xenofon Baraliakos, Filip E. van den Bosch, Floris A. van Gaalen, Lianne Gensler, Clementina Lopez-Medina, Helena Marzo-Ortega, Anna Molto, Rodolfo Perez-Alamino, Martin Rudwaleit, Marleen van de Sande, Raj Sengupta, Ulrich Weber, Sofia Ramiro

Summary: This study developed a consensual definition for 'early axial spondyloarthritis-axSpA' and 'early peripheral spondyloarthritis-pSpA' through a systematic literature review and Delphi survey. The results indicated that early axSpA should be based on symptom duration only, without considering the presence of radiographic damage.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Correction Rheumatology

Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program (Feb, 10.3899/jrheum.221022, 2023)

Atul Deodhar, Denis Poddubnyy, Proton Rahman, Jeorg Ermann, Tetsuya Tomita, Rebeca Bolce, Soyi Liu Leage, Andris Kronbergs, Caroline Johnson, Joana Araujo, Ann Leung, Desiree van der Heijde

JOURNAL OF RHEUMATOLOGY (2023)

Article Rheumatology

Robust analyses for radiographic progression in rheumatoid arthritis

Robert Landewe, Luna Sun, Yun-Fei Chen, Daojun Mo, Desiree van der Heijde

Summary: Demonstrating the inhibition of joint damage in rheumatoid arthritis trials is commonly achieved through statistically significant differences in radiographic progression measured by the mTSS. The frequently used ANCOVA+LE method for handling missing data may not be ideal for long-term extension or paediatric studies. The RC model shows better performance in terms of bias, RMSE, power and type I error rate, making it a more sensitive and precise alternative for analysing mTSS in studies with missing data.

RMD OPEN (2023)

Article Rheumatology

Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies

Xenofon Baraliakos, Atul Deodhar, Desiree van der Heijde, Marina Magrey, Walter P. Maksymowych, Tetsuya Tomita, Huji Xu, Ute Massow, Carmen Fleurinck, Alicia M. Ellis, Thomas Vaux, Julie Shepherd-Smith, Alexander Marten, Lianne S. Gensler

Summary: Bimekizumab (BKZ), a monoclonal antibody that inhibits IL-17F and IL-17A, demonstrated sustained efficacy in patients with axial spondyloarthritis (axSpA) at Week 52. The dual inhibition of IL-17A and IL-17F resulted in significant improvements compared to placebo and the safety profile was consistent with previous findings.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Do fatty lesions explain the effect of inflammation on new syndesmophytes in patients with radiographic axial spondyloarthritis? Results from the SIAS cohort and ASSERT trial

Rosalinde Stal, Sofia Ramiro, Desiree van der Heijde, Floris A. van Gaalen, Xenofon Baraliakos, Pedro M. Machado, Manouk de Hooge, Rosaline van den Berg, Monique Reijnierse, Juergen Braun, Robert Landewe, Alexandre Sepriano

Summary: In patients with radiographic axial spondyloarthritis, vertebral corner inflammation can lead to the development of syndesmophytes, but only a small portion of this effect is explained by vertebral corner fat deposition.

RMD OPEN (2023)

暂无数据